All In Biotech

Drug Trial Radar · NCT07950462

A Phase 1 Study of QLS7402 Injection in Adult Participants With Overweight or Obesity

A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Dose of QLS7402 Injection Administered Subcutaneously in Adult Participants With Overweight or Obesity

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jan 13, 2027

Primary completion

Oct 29, 2027

Study completion Apr 30, 2028

Sponsor

Sponsor type
Industry
First posted
Nov 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending dose of QLS7402 injection administered subcutaneously in adult participants with overweight or obesity

Conditions

  • Overweight or Obesity

Interventions

  • QLS7402 InjectionDrug

    QLS7402 Injection

  • Placebo controlDrug

    Placebo Control

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-emergent adverse events (TEAEs)Time frame: 169 days
  2. Number of participants with treatment-related adverse events (TRAEs)Time frame: 169 days
  3. Number of participants with serious adverse events (SAEs)Time frame: 169 days
  4. Number of participants with abnormal physical examination, 12-lead ECG and clinical laboratory testsTime frame: 169 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.